Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

Both serendipity and good science led, by 1968, to the linkage of this antigen to viral hepatitis, a link that transformed the study of hepatitis, protected the blood supply, led to a hepatitis B ...

Inside the hepatocytes, HBV produces a surplus of viral antigens, including hepatitis B e antigen (HBeAg) and hepatitis B s antigen (HBsAg), which is HBV’s envelope protein. In addition to the ...

Recent transfusion of immunoglobulin-containing products. The presence of antibodies without viral antigen or DNA. The presence of IgG anti-HBcAb but lack of IgM anti-HBcAb antibody (in our case ...

Use the purifier to isolate the hepatitis B antigen produced by the yeast cells. The vaccine, once administered, will stimulate the immune system to attack the antigen (i.e., the protein coat).

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human immunoglobulin G1 (IgG1) monoclonal antibody, brelovitug, to treat chronic ...

Researchers analysed over 6,000 serum samples from blood tests ordered by GPs which had been tested in eight hospital laboratories around the country for the presence of Hepatitis B surface antigen ...

Brelovitug is a fully human immunoglobulin G1 monoclonal antibody that targets hepatitis B virus surface antigen (HBsAG). By binding to HBsAg, brelovitug is expected to neutralize and clear hepatitis ...

Antibody concentrations ≥10mIU/mL against ... For Engerix-B, this assessment should include consideration of the mother’s hepatitis B antigen status and the high probability of maternal ...

Brelovitug is a fully human immunoglobulin G1 monoclonal antibody that targets hepatitis B virus surface antigen (HBsAG). By binding to HBsAg, brelovitug is expected to neutralize and clear ...

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...